Skip to main navigation Skip to search Skip to main content

The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence

  • Vincent Planche
  • , Suzanne Schindler
  • , David S. Knopman
  • , Giovanni Frisoni
  • , Douglas Galasko
  • , Joshua D. Grill
  • , Lon Schneider
  • , Jason Karlawish
  • , Nicolas Villain

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Article numbere70068
JournalAlzheimer's and Dementia
Volume21
Issue number4
DOIs
StatePublished - Apr 2025

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this